Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Dasatinib

One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)

DRUG

Combination of Bendamustine + Dasatinib

"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"

DRUG

Dasatinib

One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)

DRUG

Combination of Bendamustine + Dasatinib

"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"

Trial Locations (3)

11040

Local Institution, New Hyde Park

37203

Local Institution, Nashville

43210

Local Institution, Columbus

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00872976 - Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter